Tag Archives: Chemotherapy

Advisory Panel Rejects Avastin For Breast Cancer Treatment

By George Koroneos | Published: July 21, 2010
An FDA advisory panel on Tuesday voted 12–1 to discontinue Avastin (bevacizumab) as a treatment for advanced breast cancer due to post-market studies stating that the treatment does not to increase patient lifespan by any significant length of time. This is a huge problem for Roche who purchased the treatment as part of its merger with [...]
Posted in FDA, Safety | Also tagged , , , , , , , | 1 Comment

Avastin Study Shows Promising Data for Cancer Patients

By George Koroneos | Published: June 8, 2010
Genentech released the results of its Phase III Avastin study showing that women that take the ovarian cancer treatment in tandem with chemotherapy had a 39 percent improvement in the likelihood of living longer without the disease worsening than patients being treated with just chemotherapy. The data was released at the annual meeting of American Society [...]
Posted in R&D | Also tagged , , , | Leave a comment

Latest News from ASCO: Winners, Losers, and Also Rans

By Walter Armstrong | Published: June 3, 2009
Image via Wikipedia Due to pharma’s voluntary moratorium on doling out totefuls of freebies and all the lattes you can swallow, thousands of docs, researchers, and reporters had only their sleep-deprived selves to carry from data dump to data dump at this week’s American Society of Clinical Oncology (ASCO) annual confab in Orlando, Florida. Some 4,000 studies [...]
Posted in Events | Also tagged , , , , , | 2 Comments